BioSpace News Archive

NRG Therapeutics Ltd (“NRG” or “company”), an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has received a highly competitive Biomedical Catalyst (BMC) award to fund pre-clinical development of its novel small molecule disease-modifying medicines for the treatment of Parkinson’s disease, motor neuron disease (MND) and other debilitating chronic neurodegenerative disorders.

The non-profit cancer research foundation Cancer Antibodies Inc., will be presenting their breakthrough method to detect unique antigenic targets on the surface of cancer cells at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO).

PatientView is today publishing the results of its latest ‘Corporate Reputation of Pharma’ survey—cancer edition, now in its 9th year, and two years into the Covid-19 pandemic.

POXEL SA (Euronext: POXEL - FR0012432516), today announces that the Poxel team will participate in several upcoming investor and scientific conferences in June 2022.

The Lundquist Institute announced that it has received a grant of $112,000 from the Johnny Carson Foundation to support the training of the next generation of chronic obstructive pulmonary disease researchers at its Institute of Respiratory Medicine and Exercise Physiology, a world-leading venue for respiratory medicine research spanning basic and clinical science.

Kashiv Biosciences, LLC (“Kashiv” or the “Company”) is pleased to announce that the U.S. Food and Drug Administration (“FDA”) has approved its Biologics License Application (“BLA”) for pegfilgrastim-pbbk, a biosimilar referencing Neulasta®.

According to Vision Research Reports, the global biopsy guidance system market size is expected to be worth around US$ 1,883.5 Million by 2030 and is predicted to grow at a CAGR of 5.9% during forecast period 2021 to 2030.

According to Vision Research Reports, the global Healthcare ERP Market size is expected to worth around US$ 15.3 billion by 2030 and is projected to grow at a CAGR of 8.6% during forecast period 2021 to 2030.

Foghorn® Therapeutics Inc. announced management’s participation in the following investor conferences.

Tonix Pharmaceuticals Holding Corp. announced that its Board of Directors has approved a share repurchase program pursuant to which the Company may repurchase up to $12.5 million in value of its outstanding common stock, par value, $0.001 per share, from time to time on the open market and in privately negotiated transactions subject to market conditions, share price and other factors.